A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

This publication has 19 references indexed in Scilit:

• Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
  European Journal Of Cancer, 2007
• Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
  Journal of Clinical Oncology, 2007
• Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status
  Journal of Clinical Oncology, 2006
• Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2006
• Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
  Journal of Clinical Oncology, 2005
• Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
  Clinical Cancer Research, 2004
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• The Hallmarks of Cancer
  Cell, 2000
• Biological Response to ErbB Ligands in Nontransformed Cell Lines Correlates with a Specific Pattern of Receptor Expression
  Endocrinology, 1998
• Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations
  Published by Elsevier ,1996